Sunday, August 24, 2025

Latest

Moderna Expands Manufacturing Abilities In Spain, Steps Into New Asian Markets

Moderna Inc (NASDAQ: MRNA) is looking to scale up the production of its mRNA vaccines and therapeutics on a global level. The firm this morning announced a significant expansion within Asian markets, following the news last night that the company is expanding its operations in Spain.

In terms of its operations in Spain, the firm last night indicated it has expanded a long-term collaboration agreement that was previously in place. The collaboration, which is with its partner Laboratorios Farmacéuticos Rovi, S.A, will see the expansion of current capacity for the manufacturing of Moderna’s products within the country.

Presently, Rovi operates several facilities near Madrid where Moderna’s vaccines are produced. The new arrangement expands the working agreement between the two firms for a period of ten years. Presently, the arrangement will see the scaling of the manufacturing of COVID-19 vaccines, while in the future the agreement will facilitate the production of future mRNA vaccine candidates. Included in the arrangement is a series of investments that are said to support the purchase of additional equipment for production lines.

Products produced at the facility are currently used within countries outside of the United States.

In terms of Asian markets, the company this morning announced that it will be establishing new subsidiaries within Hong Kong, Taiwan, Singapore and Malaysia which will be used to “support the delivery of mRNA vaccines and therapeutics.” The expansion of the commercial network follows the company scaling the production of its current vaccine, as well as future mRNA vaccines and therapeutics. The drive to expand within Asian markets is a result of the region reportedly bearing “the highest burden of infectious diseases.”

Moderna’s portfolio currently consists of 40 development programs. 25 of these programs are currently in varying stages of clinical trials.

Moderna last traded at $151.12 on the Nasdaq.


Information for this briefing was found via Edgar and the companies mentioned. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

G Mining Q2 Earnings: Costing Gone Wild

Aya Gold Q2 Earnings: Production Slips Amid Ramp Up

i-80 Gold Q2 Earnings: Better, But Not Great

Recommended

Emerita Resources Expands El Cura Drill Program By 10,000 Metres As Deposit Remains Open For Expansion

ESGold Signs MOU For Tailings Project In Colombia With Grades Up To 42 g/t Gold, 280 g/t Silver

Related News

Moderna and Merck & Co: mRNA Cancer Vaccine Shows “Highly Encouraging Results,” Shares Rise

On Tuesday, Moderna (NASDAQ: MRNA) announced that their personalized cancer-vaccine program was successful in a...

Wednesday, December 14, 2022, 01:06:00 PM

New COVID Variant Sweeps China, Is North America Next?

Remarkably, the world could be facing another bout with COVID this year, and with negative...

Thursday, May 25, 2023, 07:35:00 AM

Moderna To Construct Manufacturing Facility In Australia Under New Strategic Partnership

Moderna Inc (NASDAQ: MRNA) is officially going to the land down under. The company late...

Thursday, March 24, 2022, 08:53:32 AM

No, The CEO Of Moderna Didn’t Just Dump $400 Million In Shares

The trouble with social media, is that it’s a big game of telephone. One individual...

Sunday, February 13, 2022, 02:50:29 PM

Internal Moderna Report Tags Elon Musk, Novak Djokovic, and Russell Brand as ‘High Risk’

Moderna (NASDAQ: MRNA), the Boston-based pharmaceutical company known for its mRNA Covid-19 vaccine, has reportedly...

Tuesday, November 28, 2023, 01:06:00 PM